Jazz Pharmaceuticals (JAZZ) news
Recent news
Jazz Pharmaceuticals - Ziihera U.S. prescribing information contains boxed warnings for diarrhea and embryo-fetal toxicity
Jazz Pharmaceuticals has issued updated U.S. prescribing information for ZIIHERA (zanidatamab-hrii), which includes boxed warnings for severe diarrhea and embryo-fetal toxicity. The drug, approved for the treatment of adults with previously treated, unresectable or metastatic HER2-positive biliary…
AInvest Wire · 9h agoJazz to submit Ziihera GEA data to global regulators
AInvest Wire · 9h agoJazz Pharmaceuticals: Safety profile of Ziihera in combination with chemotherapy generally consistent with known safety profile
AInvest Wire · 9h agoJazz Pharmaceuticals - Ziihera plus Tislelizumab and chemotherapy improves OS hazard ratio, supporting new standard of care
Jazz Pharmaceuticals has received U.S. Food and Drug Administration (FDA) approval for Ziihera® (zanidatamab-hrii) in combination with Tislelizumab-jsgr and chemotherapy for the first-line treatment of adults with HER2-positive gastroesophageal adenocarcinoma . This approval marks a significant…
AInvest Wire · 9h agoJazz Pharmaceuticals - Herizon-GEA-01 results reinforce Ziihera as definitive HER2-targeted backbone in first-line GEA
AInvest Wire · 9h agoLight Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.